Compare
Amgen vs Krystal Biotech (AMGN vs KRYS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Krystal Biotech (KRYS) +50.5%; so far this year the figures are +40.7% and +22.0%.
Amgen is the larger company by market value, about 27.9 times the size of Krystal Biotech.
On trailing earnings, AMGN trades at 26.7 times and KRYS at 40.8 times.
Revenue grew +8.2% at AMGN and +26.0% at KRYS over the last year.
AMGN yields 2.16%. KRYS pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | KRYS | |
|---|---|---|
| Price | $460.42 | $300.88 |
| 1-day | +0.03% | +0.21% |
| YTD | +40.67% | +22.04% |
| 1 year | +43.94% | +50.53% |
| 3 years | +76.51% | +152.18% |
| Market cap | $249.1B | $8.9B |
| P/E | 26.7 | 40.8 |
| P/S | 6.40 | 18.97 |
| P/B | 17.35 | 6.21 |
| Revenue growth | +8.20% | +26.00% |
| EPS growth | +33.30% | +10.30% |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | 47.9 |
| ROE % | 65.4 | 15.7 |
| Debt / equity | 3.76 | 0.00 |
| FCF yield % | 3.8 | 3.5 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.75 |
| RSI (14) | 60.5 | 39.9 |
| Technical rating |